Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

Benzinga · 3d ago
Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.